One of the main challenges in many neurological and meurodegenerative disorders, such as Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and others, is to diagnose the disease in an earlier stage. These diseases are currently being diagnosed when much of the brain damage, which is irreversible, had already occur. Thus, it is crucial to develop methods for earlier identification of these patients, so that once treatment is available, it could be given at a much earlier stage to prevent the brain damage.


We aim to perform a large scale genetic screening of healthy populations that are being prospectively followed up, and to map the genetic factors that are associated with progression to different neurological conditions.

Population genetics

    1033 Pine Avenue West

    Ludmer Pavilion, room 312

    Montreal, QC, H3A 1A1

    Lab: +1-514-398-5845